title: Transcatheter aortic valve implantation in a patient with myelofibrosis and severe thrombocytopenia.
abstract: Transcatheter aortic valve implantation (TAVI) has been commonly used to treat patients with aortic stenosis who have a contraindication to, or a high risk of, corrective surgery. Anti-thrombotic treatment is an important part of the TAVI procedure to avoid thrombotic complications during both peri- and post-procedural periods. However, no specific data are available regarding the safety of TAVI with or without anti-thrombotic treatment, either during the surgical procedure or follow up period in patients with thrombocytopenia, such as myelofibrosis. Here, the case is reported of a patient with myelofibrosis and severe thrombocytopenia who underwent a TAVI procedure without anti-thrombotic treatment such as heparin, acetyl salicylic acid, or clopidogrel.
authors.forename: Hakan
authors.initials: H
authors.lastname: Erkan
authors.forename: Levent
authors.initials: L
authors.lastname: Korkmaz
authors.forename: Gülhanim
authors.initials: G
authors.lastname: Kiriş
authors.forename: Sükrü
authors.initials: S
authors.lastname: Celik
mesh_terms: D000368:Aged; D001024:Aortic Valve Stenosis / Q000150:complications* / Q000628:therapy*; D005471:Fluoroscopy; D006801:Humans; D008297:Male; D055728:Primary Myelofibrosis / Q000150:complications*; D013921:Thrombocytopenia / Q000150:complications*; D065467:Transcatheter Aortic Valve Replacement / Q000379:methods